



		<b>EMLc</b>	<b>ATC codes: J05AB04</b>
<b>Indication</b>	Viral haemorrhagic fever, not elsewhere classified	<b>ICD11 code: 1D86</b>	
<b>INN</b>	Ribavirin		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Core		
<b>Additional notes</b>	For the treatment of viral haemorrhagic fevers.		
<b>Formulations</b>	Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution ; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg ; 400 mg ; 600 mg		
<b>EML status history</b>	First added in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Wikipedia</b>	<a href="#">Ribavirin</a> 		
<b>DrugBank</b>	<a href="#">Ribavirin</a> 		

## Summary of evidence and Expert Committee recommendations

Ribavirin was added to the main list in March 2007 for use for viral haemorrhagic fevers, including use in children. The Subcommittee recommended that this be included on the list as essential for children but, given concerns about potential inappropriate use of this medicine in children, added a note that it was for the treatment of viral haemorrhagic fevers only.

